A PKA inhibitor
PKI (14-22) amide (myristoylated) is a cell-permeable peptide inhibitor of protein kinase A (PKA).1,2,3 It inhibits PKA activity in mouse brain or spinal cord lysates when used at a concentration of 75 µM.1 PKI (14-22) amide (myristoylated) reduces IgG-dependent phagocytosis of heat-killed S. cerevisiae by isolated human neutrophils in a concentration-dependent manner.2 It inhibits the replication of several strains of Zika virus, including IbH 30656, MR766, H/FP/2013, and PRVABC59, in human umbilical vein endothelial cells (HUVECs; IC50s = 17.75, 22.29, 34.09, and 19.19 µM, respectively).3 PKI (14-22) amide (myristoylated) (2.5 nmol, i.c.v.) increases latency to tail withdrawal in the tail-flick test in morphine-tolerant mice.1
1.Dalton, G.D., Smith, F.L., Smith, P.A., et al.Alterations in brain Protein Kinase A activity and reversal of morphine tolerance by two fragments of native Protein Kinase A inhibitor peptide (PKI)Neuropharmacology48(5)648-657(2005) 2.Ydrenius, L., Majeed, M., Rasmusson, B.J., et al.Activation of cAMP-dependent protein kinase is necessary for actin rearrangements in human neutrophils during phagocytosisJ. Leukoc. Biol.67(4)520-528(2000) 3.Cheng, F., da Silva, S.R., Huang, I.-C., et al.Suppression of Zika virus infection and replication in endothelial cells and astrocytes by PKA inhibitor PKI 14-22J. Virol.92(4)e02019-02017(2018)
动态评分
0.0